SUMM Summit Therapeutics

Block Listing Six Month Review

Block Listing Six Month Review

BLOCK LISTING SIX MONTHLY RETURN

 (Note: Italicised terms have the same meaning as given in the Listing Rules.)

Date: 3 October 2019

Name of applicant:Summit Therapeutics plc
Name of scheme:2005 EMI Scheme
Period of return:From:31 Mar 2019To:30 Sept 2019
Balance of unallotted securities under scheme(s) from previous return:776,756
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):Zero
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):Zero
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:476,756



Name of applicant:Summit Therapeutics plc
Name of scheme:2016 Long Term Incentive Plan
Period of return:From:31 Mar 2019To:30 Sep 2019
Balance of unallotted securities under scheme(s) from previous return:4,196,863
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):Zero
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):Zero
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:4,196,863



Name of contact:Richard Pye
Telephone number of contact:+44 (0)1235 443951

This figure has been reduced since the last block list review to reflect the number of share options that remain in existence under the 2005 EMI Scheme. This change is due share options issued under the 2005 EMI Scheme having lapsed due to employees leaving the Company. No new share options will be issued under the 2005 EMI Scheme.

EN
03/10/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Summit Therapeutics

 PRESS RELEASE

AIM Delisting Reminder

AIM Delisting Reminder Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) AIM Delisting Reminder Oxford, UK, and Cambridge, MA, US, 11 February 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, issues a reminder that, as previously announced and pursuant to AIM Rule 41, the Company’s ordinary shares of one penny nominal value (“Ordinary Shares”) will cease to be admitted to trading on AIM at 7.00 am on 24 February 2020. Accordingly, the final day of trading on AIM of the Company’s Ordinary Shares will be 21 February 2020. The Company’s ...

 PRESS RELEASE

Director/PDMR Shareholding

Director/PDMR Shareholding Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Notification of Transaction of Persons Discharging Managerial Responsibilities Oxford, UK, and Cambridge, MA, US, 10 February 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that it has received notification that on 7 February 2020, Dr Elaine Stracker, a Non-Executive Director of the Company, was assigned for no consideration warrants to acquire a total of 2,099,207 ordinary shares by Maky Zanganeh and Associates, Inc. (“MZA”). The Company has a con...

 PRESS RELEASE

Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eur...

Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma Milestone Based on Achievement of Patient Enrolment Target in Phase 3 Clinical Trials of Ridinilazole Oxford, UK, and Cambridge, MA, US, 6 February 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it achieved the first milestone under its license and collaboration agreement with Eurofarma Laboratórios SA (‘Eurofarma’). The $1.0 milli...

 PRESS RELEASE

Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conferen...

Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference Oxford, UK, and Cambridge, MA, US, 4 February 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Mr Glyn Edwards, Chief Executive Officer, will present at the 2020 BIO CEO & Investor Conference on 10 February 2020 at 2:15pm EST in New York City. A live webcast of the presentation will be available in the Investors section of the Company's website, . A replay ...

 PRESS RELEASE

Exercise of Restricted Stock Units

Exercise of Restricted Stock Units Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Exercise of Restricted Stock Units Oxford, UK, and Cambridge, MA, US, 27 January 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that following the exercise of restricted stock units by former directors, the Company has issued 269,230 new ordinary shares of one penny each (the “New Ordinary Shares”). Application has been made for the admission to trading on AIM of the New Ordinary Shares, which will rank pari passu with the Company’s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch